U.S. stocks rallied sharply Monday, driven by renewed appetite for AI-related equities and growing confidence that the Federal Reserve could deliver a December interest rate cut. At the close, the Dow Jones Industrial Average jumped 1.5%, the S&P 500 rose 1.4%, and the tech-heavy NASDAQ surged 2.7%. Despite the strong session, major indexes remain on track for a weak November, with the S&P 500 down 3.5% month-to-date, the NASDAQ lower by 6.1%, and the Dow off 2.8%.
Tech stocks led the recovery as Alphabet shares soared more than 6%. Investor enthusiasm grew after the company’s Gemini AI model received a significant upgrade, intensifying competition with OpenAI. A leaked memo suggested OpenAI CEO Sam Altman acknowledged Google’s momentum could create “temporary economic headwinds.” Other AI leaders, including NVIDIA and Oracle, also posted solid gains, reinforcing optimism around the sector’s long-term growth.
Rate-cut expectations strengthened after recent comments from key Federal Reserve officials. New York Fed President John Williams signaled support for a December cut, a stance echoed by Fed Governor Christopher Waller, who noted that economic conditions have not shifted meaningfully since the last policy meeting. According to the CME FedWatch Tool, the probability of a 25-basis-point cut has climbed to nearly 69%, up from 44% just a week ago.
Investors now await a wave of delayed U.S. economic data, including producer inflation, retail sales, industrial production, and third-quarter GDP. Signs of slowing growth or a cooling labor market could bolster the case for more easing, though the Fed will meet in December without November’s full payroll data.
Geopolitical sentiment also improved after President Trump accepted an invitation to meet Chinese President Xi Jinping in April, raising hopes of progress in U.S.–China trade relations.
In corporate news, Agilent Technologies is set to report earnings after the close, while Novo Nordisk shares tumbled following weak Alzheimer’s trial results. Biogen stock climbed as analysts suggested Novo Nordisk’s setback could boost Biogen’s Alzheimer’s drug Leqembi.


Australia Consumer Sentiment Rises in July as Fuel Price Relief Lifts Confidence
Dollar Holds Steady Ahead of U.S. CPI as Oil Surge, Middle East Tensions Keep Markets on Edge
Asian Stocks Slide as Oil Surge, U.S.-Iran Tensions and Fed Rate Bets Weigh on Markets
Asian Currencies Stay Rangebound as Middle East Tensions, Weak China GDP Weigh on Sentiment
South Korea’s KOSPI Enters Bear Market Despite Remaining 2026’s Best-Performing Major Stock Index
US Inflation Expected to Ease in June, but Fed Rate Hike Risks Persist Amid Middle East Tensions
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List
Gold Price Holds Near Record High as Cooling U.S. Inflation Offsets Fed Caution
China Home Prices Fall Again in June Despite Slower Pace of Decline
ECB's Kocher Says No Inflation Spillover Yet From Iran Conflict, Warns Risks Remain
Gold Prices Slip as Oil Rally Fuels Inflation Fears, Strengthens Dollar
Asian Currencies Hold Steady as Middle East Tensions Offset Weaker US Dollar
Japanese Yen Holds Steady as Intervention Hopes Grow Ahead of U.S. CPI Data
South Korea Raises Interest Rates to 2.75% as Inflation and Weak Won Drive Tightening
Port of Los Angeles Posts Record June Cargo Volume as Importers Rush Ahead of U.S. Tariffs
IEA Warns China Rare Earth Export Curbs Could Threaten $6.5 Trillion in Global Production
China Q2 2026 GDP Misses Forecast as Weak Domestic Demand Offsets Export Strength 



